Neogen Chemicals Ltd - 542665 - Certificate Under Regulation 40 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 ('SEBI Regulations') For The Financial Year Ended March 31, 2024.
Certificate under Regulation 40(9) of SEBI Listing Regulations for the Financial Year ended March 31, 2024. Neogen Chemicals Ltd - 542665 - Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Compliance Certificate pursuant to Regulation 7(3) of SEBI (listing obligations and disclosure requirement) Regulations 2015. Neogen Chemicals Ltd - 542665 - Closure of Trading Window
The Intimation of Trading Window closure for dealing in securities of the Company for all the designated person and its immediate relative, connected persons and legitimate insiders of the Company from April 1, 2024 till the end of 48 hours after the declaration of Audited Financial Results of the Company for the quarter and financial year ended March 31, 2024. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Analyst/Investor Meet. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Credit Rating
Intimation of Credit Rating by ICRA Limited. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor Meet to be held on March 1, 2023 at Trident BKC Mumbai. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earnings conference call for discussing Q3FY24 results held on February 12, 2024. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of earnings conference call for discussing Q2FY24 results held on February 12, 2024. Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring agency report issued by CRISIL Ratings Limited dated February 14, 2024 for the quarter ended December 31, 2023 w.r.t. utilization of proceeds raised through preferential issue of equity shares.
